Pillar Biosciences snaps up $29.7m
Boston and Shanghai-based Pillar Biosciences, an NGS clinical cancer diagnostics company, has secured $29.7 million in Series C preferred stock financing.
Boston and Shanghai-based Pillar Biosciences, an NGS clinical cancer diagnostics company, has secured $29.7 million in Series C preferred stock financing.
Copyright PEI Media
Not for publication, email or dissemination